IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.27
+8.65%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$4.09
From 52W high−29.65%
Volume1.16M
Market cap$355.25M
P/E (TTM)—
P/S (TTM)36.0x
Div yield—
Key dataNov 4, 2026
Open
$4.09
From 52W high
−29.65%
Volume
1.16M
Market cap
$355.25M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.9x
P/E (TTM)
—
RSI (14)
53.6
MomentumView details →
1D Return
+8.65%
YTD Return
+108.96%
SummaryUpdated Jun 1, 2026
Opus Genetics, Inc. (NASDAQ:IRD) is a clinical-stage ophthalmic biopharmaceutical company founded in 2018 and headquartered in Farmington Hills, Michigan. Originally known as Ocuphire Pharma, Inc., the company went public in 2015 and focuses on developing innovative therapies for patients with refractive and retinal eye disorders. The company operates in the specialized field of ophthalmology, targeting unmet medical needs in eye care through both commercially available products and an active clinical development pipeline.
Similar companies
Latest newsMore news →
Opus Genetics approved equity awards under its 2021 Inducement Plan for 10 new non-executive employees as an inducement to employment.2d agoThe U.S. Food and Drug Administration cleared Opus Genetics, Inc.’ IND application for OPGx-RDH12, enabling clinical development for RDH12-associated Leber congenital amaurosis.15d ago